The U.S. Food and Drug Administration (FDA) has granted approval for a dwarfism treatment for extended use of once-daily injections to treat children under age 5 with short limb dwarfism.
According to Reuters, the drug in 2021 that contains the active ingredient “Vosoritide” was the first treatment to receive the green light from the Food and Drug Administration (FDA) to treat the genetic disorder, known as “achondroplasia,” which is a bone growth disorder and the most common cause of dwarfism. In children aged five years and over.
The report explained that the genetic disorder “achondroplasia” is a form of disproportionate short stature resulting from a mutation in the gene, which occurs in about one in every 25,000 newborns.
The report indicated that the US Food and Drug Administration’s decision regarding expanded use was supported by trial data that showed that the treatment showed effectiveness and safety in children under the age of 5 years, compared to those aged 5 years and above.
The report confirmed that the drug, approved in Europe, Australia and Brazil for children aged two years and older, and in Japan for use in children of all ages, is also under review in Europe to expand the use of injections in children aged four months and older.
Treatment of dwarfism
President Abdel Fattah El-Sisi had launched an initiative in February 2019 for a national survey of anemia, obesity, and stunting among school students, targeting about 11 and a half million students, both male and female, in the governorates of Upper Egypt and Bahri.
The initiative’s services include conducting medical surveys for students and measuring weight, height, and hemoglobin levels in the blood, to detect malnutrition diseases, and developing the necessary mechanisms to improve their health, in coordination with the Ministry of Education and Technical Education. Cases infected with any of these diseases covered by the initiative are referred to clinics. Health insurance, to complete the necessary examinations and dispense treatment for free. These students are also given a “follow-up card” containing their personal data, to follow up on them periodically and check on their health condition continuously through 255 health insurance clinics in all governorates of the Republic.
2023-10-22 08:06:00
#FDA #approves #drug #treat #dwarfism #children #years
